Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase

NCT04070443 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

170

Enrollment

OTHER

Sponsor class

Conditions

Philadelphia Chromosome Positive CML
BCR-ABL Positive Chronic Myelogenous Leukemia

Interventions

DRUG: Ponatinib
DRUG: Imatinib

Sponsor

Centre Leon Berard